ADAP Advocacy has released a retrospective white paper examining the 340B Drug Pricing Program, arguing that reform is necessary to realign the program with its original legislative intent of helping low-income and uninsured patients. The paper, titled "340B Program: The Glue That Should Hold Our Healthcare System Together," outlines how the program has grown into the second-largest federal prescription drug program in the United States, behind Medicare Part D, but has prioritized provider interests over patient interests.
The white paper highlights three central questions driving the call for greater transparency: If 340B is designed to expand access and reduce financial burden, why are patients increasingly unable to afford care? Why is 340B not adequately addressing this problem? And why is it failing to meet the needs of the uninsured and underinsured, the very persons it was designed to serve? According to the paper, the program's growth has outpaced the ability to clearly see how it is actually helping patients.
Brandon M. Macsata, CEO of ADAP Advocacy, stated: "There is an ongoing effort to push for greater transparency across multiple layers of this country's fragmented healthcare system, including hospitals' patient billing practices and pharmacy benefit managers' spread pricing policies. The 340B Program shouldn't be excluded from this broader effort, especially since the ultimate goal is improved program efficiency, leading to greater access to care and treatment for low-income patients."
The white paper argues that a program of this size and importance cannot be entrusted to good faith alone; improved accountability and transparency guardrails are needed to ensure its success and ultimately benefit its intended beneficiaries: patients. The full white paper is available at https://www.adapadvocacy.org/policycenter/340b.
The 340B Drug Pricing Program requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations at significantly reduced prices. However, critics argue that the program lacks oversight, allowing covered entities to profit without ensuring patient benefits. ADAP Advocacy's white paper contributes to the ongoing debate about healthcare transparency and the need for reforms that prioritize patient access and affordability.
ADAP Advocacy's mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improve access to care for persons living with HIV/AIDS. The organization works with advocates, community, health care, government, patients, pharmaceutical companies and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.
